Here are three quick notes:
1. Firms covering the shares have a one-year price target of $87.88.
2. On Dec. 1, 2016, Robert Baird rated the shares a “buy.”
3. During the second quarter last year, LS Investment Advisors increased its position in AmSurg by 68.7 percent.
More articles on surgery centers:
5 statistics on ENT net revenue per case in ASCs
Mount Sinai establishes Eye and Vision Research Institute: 4 key notes
Nobilis Health Corp. to acquire Hamilton Vein Center for $13.3M — 4 points
